When was C₂N Diagnostics founded?

C₂N Diagnostics was founded in 2007 and raised its 1st funding round 2 years after it was founded.

Where is C₂N Diagnostics located?

C₂N Diagnostics is headquartered in St. Louis, United States.

How many employees does C₂N Diagnostics have?

As of May 31, 2026, the latest employee count at C₂N Diagnostics is 113.

Is C₂N Diagnostics a funded company?

C₂N Diagnostics is a funded company, having raised a total of $35M across 12 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 22, 2009.

When was the latest funding round of C₂N Diagnostics?

C₂N Diagnostics' latest funding was a $***** Conventional Debt round on May 12, 2025, with participation from 0 investor.

Where does C₂N Diagnostics rank among its competitors?

C₂N Diagnostics ranks 1st amongst 44 active competitors, of which 18 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was ALZpath, which secured $8.41M in Jul, 2026.

Who are the top competitors of C₂N Diagnostics?

C₂N Diagnostics' top competitors include ALZpath, NeuroDex and Amydis Diagnostics. Among them, ALZpath secured the most recent funding round in July, 2026.

C₂N Diagnostics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of diagnostics and therapies for Alzheimer's disease. The product include PrecivityAD blood test that is intended for use in patients with cognitive impairment and to determine the presence or absence of amyloid plaques in the brain. It also offers bioanalytical services for pharmaceutical and biotechnology companies.

Website: c2n.com
Social
Email ID: *****@c2ndiagnostics.com
Phone Number: +1 **********

Key Metrics

Founded Year

2007

Location

St. Louis, United States

Stage

Series B

Total Funding

$35M in 12 rounds

Latest Funding Round

Conventional Debt, May 12, 2025, $*****

Investors

Eisai & 7 more

Ranked

1^st among 44 active competitors

Employee Count

113 as on May 31, 2026

Similar Companies

ALZpath & 57 more

View C₂N Diagnostics' full profile

C₂N Diagnostics has raised a total funding of $35M over 12 rounds. Its first funding round was on Sep 22, 2009. C₂N Diagnostics has 8 institutional investors.

Here is the list of recent funding rounds of C₂N Diagnostics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 12, 2025	5772151	Conventional Debt	6877268	2739140	5389911	5271957
Mar 13, 2025	6403886	Series B	1215201	8420327	6464487	Samsung Venture Investment & 3 more
Oct 01, 2024	6659628	Grant (prize money)	2282004	8374329	7546860	GHR FOUNDATION

Access funding benchmarks and valuations. Sign up today!

View details of C₂N Diagnostics's funding rounds and investors

The founders of C₂N Diagnostics is Ilana Fogelman.

Here are the details of C₂N Diagnostics' key team members:

Ilana Fogelman: Co-Founder of C₂N Diagnostics.
Contact Info: 1 email address

View details of C₂N Diagnostics's Founder profiles and Board Members

C₂N Diagnostics' employee count trend

C₂N Diagnostics has 113 employees as of May 26. Here is C₂N Diagnostics's employee count trend over the years:

Employee count trend for C₂N Diagnostics

Uncover C₂N Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of C₂N Diagnostics include ALZpath, NeuroDex and Amydis Diagnostics. Here is the list of Top 10 competitors of C₂N Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	C₂N Diagnostics 2007, St. Louis (United States), Series B	Developer of diagnostics and therapies for Alzheimer's disease	$35M	Samsung Venture Investment, Samsung BioLogics ... & 6 others	58/100
2nd	ALZpath 2020, Carlsbad (United States), Series A	Developer of diagnostic solutions for Alzheimer's Disease	$8.41M	Stead Impact Ventures, Alzheimer's Drug Discovery	55/100
3rd	NeuroDex 2018, Natick (United States), Seed	Manufacturer of diagnostic tools for Alzheimer's disease	$1.36M	ICV, HHS & 1 others	54/100
4th	Amydis Diagnostics 2013, San Diego (United States), Series A	Developer of diagnostics test for detection of Alzheimer's disease	$8.69M	NIA, Springboard Enterprises & 4 others	53/100
5th	Todos Medical 2009, Rehovot (Israel), Public	Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders	-	Lincoln Park Capital, Yozma & 2 others	47/100
6th	DiamiR 2009, Monmouth Junction (United States), Funding Raised	Developer of minimally invasive diagnostic tests	-	NIA, HHS	45/100
7th	ADmit Therapeutics 2017, Barcelona (Spain), Series A	Provider of diagnostic services for early detection of Alzheimer's disease	$12.9M	Ship2B, Europa & 13 others	42/100
8th	Lucent Diagnostics 2023, Billerica (United States), Unfunded	Developer of a biomarker blood test for the diagnosis of Alzheimer's disease	-	-	40/100
9th	bioLOCKEY Healthworks 2023, Bengaluru (India), Seed	Developer of point-of-care diagnostics and novel biologics by Nanobody discovery platform	$478K	Pfizer, Pfizerindovation & 7 others	37/100
10th	Veravas 2017, Oakdale (United States), Series A	Provider of platform to manage sample preparation and diagnostic solutions	$25M	SeedFunders	37/100